This document summarizes key aspects of China's National Medical Products Administration (NMPA) and its drug registration policies and processes. It outlines NMPA's major departments and China's drug classification system. It then describes the differences between China's previous and current policies for registering imported drugs. The document provides details on NMPA's drug master file (DMF) submission process and expectations for importers. It concludes with specifics around DMF content requirements and regional requirements in China.